QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism?

• Q32 Bio is set to issue roughly 6.7 million shares of common stock at $8 per share.
• The financing round was led by BVF Partners, with participation from RA Capital Management, OrbiMed, and Atlas Venture.
• Excluding the $55 million offering, the company reported $50.8 million in cash as of March 31, 2026, which it believes is sufficient to support operations into the first half of 2028.     

Shares of Q32 Bio (QTTB) soared more than 80% on Wednesday to their highest level since December 2024 after the biotech firm unveiled a $55 million private placement priced at a 13% premium to the previous session’s close, highlighting optimism around its autoimmune disease pipeline and institutional backing.

QTTB stock is heading for its biggest-ever monthly gains.

QTTB To Issue 6.7M Shares

Q32 Bio is expected to raise around $55 million from institutional and accredited investors, with the company set to issue roughly 6.7 million shares of common stock at $8 per share, along with pre-funded warrants to purchase an additional 150,000 shares. The offering is expected to close on May 28. The stock closed at $7.09 on Tuesday.

The financing round was led by BVF Partners, with participation from RA Capital Management, OrbiMed, and Atlas Venture. Morgan Stanley served as the lead placement agent.

QTTB Expects Cash Runway To Support Operations Into 2028

Q32 Bio is currently developing treatments for immune-related diseases, with its lead drug candidate, Bempikibart, currently being tested in a Phase 2 trial for alopecia areata, an autoimmune condition in which the immune system attacks hair follicles, causing patchy hair loss.

Q32 Bio recently said Part B of its Phase 2a clinical trial remains on track, with topline 36-week data expected in mid-2026.

The company also reported $50.8 million in cash as of March 31, 2026, which it believes is sufficient to support operations into the first half of 2028. This does not include the $55 million offering.

Retail Bets Big On QTTB

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.

One user believes institutional investors like the stock.

Another user expects the stock to climb to $20, a 55% increase from current levels.

The stock has seen massive buying interest so far this year, surging more than 310%.

Read also: HOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Deals

For updates and corrections, email newsroom[at]stocktwits[dot]com.